Merck (MRK) Stock Declines While Market Improves: Some Information for Investors
Merck (MRK) concluded the recent trading session at $105.88, signifying a -1.15% move from its prior day's close.
US FDA approves Merck's drug for kidney cancer
The U.S. Food and Drug Administration on Thursday approved Merck's drug belzutifan for a type of kidney cancer.
MRNA Stock Surges as Moderna Teams Up With Merck to Fight Cancer
Moderna (NASDAQ: MRNA ) has been on a rough trajectory in recent days. Indeed, continuous declines in MRNA stock earlier this week have hurt investor sentiment in the large-cap biotechnology company.
Moderna-Merck Vaccine for Skin Cancer Shows Positive Results; Moderna Stock Jumps
A personalized vaccine developed by Moderna (MRNA) and Merck (MRK) showed significant positive results in treating skin cancer in high risk patients.
Moderna's stock rallies 7.9% after announcing positive data in trial of melanoma treatment combined with Merck's Keytruda
Moderna Inc.'s stock MRNA, +0.72% soared 7% early Thursday, after the biotech and partner Merck MRK, +2.65% announced positive data from a mid-stage trial of Moderna's mRNA-4157 in combination with...
Moderna, Merck vaccine with Keytruda delays return of deadly skin cancer after 3 years, data says
Those results build on midstage trial data Moderna and Merck released earlier this year, which examined the efficacy of the combination over a shorter period.
Merck's (MRK) Keytruda, Lenvima Endometrial Cancer Study Fails
The combination of Merck's (MRK) Keytruda and Eisai's Lenvima for the first-line treatment of advanced/recurrent endometrial carcinoma fails to meet dual primary endpoints in late-stage study.
Moderna, Merck begin late-stage study for mRNA cancer therapy
Moderna and Merck & Co said on Monday they have started a late-stage trial of their experimental personalized mRNA cancer treatment in combination with blockbuster drug Keytruda for patients with a...
Merck cancels Phase 3 lung cancer study on disappointing interim data as separate mid-stage trial fails
Merck & Co Inc (NYSE:MRK) announced on Thursday that its investigational lung cancer therapeutic combination of pembrolizumab (Keytruda) and vibostolimab failed to meet the goal of a mid-stage stud...
Merck's lung cancer drug combo fails to meet trial goal
Merck said on Thursday its experimental therapy in combination with Keytruda to treat a type of lung cancer in previously treated patients did not reach statistical significance in a mid-stage study.
Merck & Co., Inc. (MRK) Management Presents at 6th Annual Evercore ISI HealthCONx Conference (Transcript)
Merck & Co., Inc. (NYSE:MRK ) 6th Annual Evercore ISI HealthCONx Conference Transcript November 30, 2023 1:20 PM ET Executives Dr. Eliav Barr - Senior Vice President, Head, Global Clinical Developm...
Merck's (MRK) Pneumococcal Jab Shows Upbeat Responses in Study
Positive data from Merck's (MRK) phase III study on V116, an investigational, 21-valent pneumococcal conjugate vaccine, supports the immunogenicity of V116 compared to standard of care.
Merck raises quarterly dividend to 77 cents vs. 73 cents
Merck & Co. Inc. MRK said Tuesday its board has raised its quarterly dividend to 77 cents. The dividend was previously 73 cents.
Merck Will Keep Your Retirement Income Healthy
Merck is a legacy drugmaker with a history of fat margins and occasional robust growth. The company is entering a new growth phase, making it a good investment opportunity. Merck has a low forward ...
Merck (MRK) to Acquire Private Neuroscience Company for $610M
Merck (MRK) has been a shareholder in Caraway Therapeutics since 2018 through its MRL Ventures Fund.
Related Companies